Notes

Efficient management of polyneuropathy, organomegaly, endocrinopathy, M-protein, along with skin color adjustments affliction with congestive coronary heart failing: In a situation record.
PURPOSE Bismahanine, a carbazole alkaloid, has been shown to exhibit tremendous pharmacological potential. In this study, the effect Bismahanine was examined against human cervical cancer cells. METHODS The HeLa human cervical cancer cells were treated with various concentrations of Bismahanine from 0-320 μM for 24 h. The anticancer effects of Bismahanine were measured by WST-1 cell viability assay. DAPI and annexin V/propidium iodide (PI) assays were employed to examine the induction of apoptosis. Transwell assays were performed to examine the cell migration and invasion. The expression of the proteins was examined by western blot analysis. RESULTS Bismahanine decreased the viability of HeLa cells and exhibited an IC50 of 20 µM due to induction of apoptosis as indicated by DAPI staining. Additionally, the annexin V/PI staining revealed that apoptotic cell percentage increased with increasing concentration of Bismahanine. The expression of Bcl-2 was decreased while that of Bax, Caspase 3 and 9 was increased. Bismahanine treatment also resulted in significant decrease of metalloproteinase (MMP) 2 , 3 and 9 expressions. Transwell assays showed that Bismahanine inhibited the migration and invasion of HeLa cells. CONCLUSION Bismahanine exhibits significant anti-proliferative effects on the cervical cancer cells and may prove essential in the development of chemotherapy for cervical cancer.PURPOSE Being the second most prevalent cancer in females, cervical cancer causes significant mortality across the globe. Owing to the adverse effects and inefficiency of the currently used anticancer drugs, there are increasing efforts for the identification of safer and effective anticancer agents from plants. This study was undertaken to investigate the anticancer effects of Ovatodiolide, a plant-derived macrocyclic diterpenoid, against the human cervical cancer. METHODS The anticancer effects were examined by WST-1 proliferation assay. DAPI and annexin V/propidium iodide (PI) staining were used for apoptosis detection. Flow cytometry was used for cell cycle analysis. Protein expression was used for cell cycle analysis. RESULTS The results revealed that Ovatodiolide caused inhibition of the viability of all the cervical cancer cells with IC50 ranging from to 14 to 56 µM. Ovatodiolide exerted more profound antiproliferative effects on the DoTc2 cells with and IC50 of 14 µM. However, minimal cytotoxicity was observed for the normal cervical cells as evidenced from the IC50 of 100 µM. T3 activator Ovatodiolide triggered apoptotic cell death of the DoTc2 cells. The induction of apoptosis was accompanied with increase in Bax and decrease in Bcl-2 expression. Ovatodiolide also caused arrest of the DoTc2 cells at the G2/M phase of the cell cycle, which was also accompanied with suppression of cyclin B1 expression. Investigation of the effects of Ovatodiolide on NF-kB expression revealed that the molecule caused significant decrease in the expression of the NF-kB expression. CONCLUSION Taken together, Ovatodiolide may prove a lead molecule for the development of systemic therapy for cervical cancer.PURPOSE To study the efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients. METHODS A total of 100 ovarian cancer patients treated in our hospital from January 2015 to December 2018 were enrolled and divided into experimental group (n=50) and control group (n=50) using a random number table. Patients in the control group were treated with carboplatin alone, while those in the experimental group were treated with bevacizumab combined with nedaplatin, based on the treatment in the control group. The efficacy, adverse reactions and quality of life (QoL) score of patients were observed. Moreover, the levels of serum human epididymis protein 4 (HE4), alpha fetoprotein (AFP) and macrophage migration inhibitory factor (MIF), tumor markers carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and CA19.9, immunity indexes cluster of differentiation 3+ (CD3+), CD4+, CD8+ and natural killer (NK) cells, and serum inflammatory factors interleukin-8 (IL-8), IL-6 and IL-10 were detected before and after therapy. RESULTS In the experimental group, the efficacy was superior to that in control group (p0.05). After treatment, the levels of HE4, AFP and MIF, CA125, CEA and CA19.9 and inflammatory factors IL-8, IL-6 and IL-10 obviously declined in the experimental group compared with the control group (p less then 0.05), while the levels of immunity indexes CD3+, CD4+, CD8+ and NK cells were clearly increased (p less then 0.05). link2 CONCLUSION Bevacizumab combined with nedaplatin has good efficacy in the treatment of ovarian cancer, which can significantly improve the tumor markers, enhance the immunity and ameliorate the QoL of patients, with fewer adverse reactions, so it is worthy of popularization and application.PURPOSE Tormentic acid has been shown to exert remarkable anti-cancer potential against different cancer cell types. In this study, the anti-cancer potential of tormentic acid was examined in cisplatin-resistant cervical cancer cells (HeLa cells). Further, the effects of tormentic acid on cell cycle, reactive oxygen species (ROS) production, and mTOR/PI3K/AKT signalling pathway were evaluated as well. METHODS Cell viability was evaluated by MTT assay and its impact on mTOR/PI3K/AKT signalling pathway was estimated via western blot assay. Colony formation was analysed through clonogenic assay and phase-contrast microscopy was used for the determination of apoptotic cell morphology along with DAPI staining. link3 Fluorescence-activated cell sorting was performed for cell cycle analysis and ROS production was monitored by fluorescence microscopy. RESULTS The results indicated that tormentic acid significantly supresses the proliferation of HeLa cells. These antiproliferative effects of tormentic acid were dose-dependeand targeting of mTOR/PI3K/AKT signalling pathway. Thus, tormentic acid may be considered as a lead molecule in cancer therapeutics.PURPOSE Although pain is a common event during treatment of cancer, its assessment and management remains suboptimal in everyday clinical practice at global level. METHODS Considering both the important role of internet in daily life and that clinical guidelines are important for translating evidence in clinical practice, we performed a prospective study to scrutinize the magnitude of updated evidence-based cancer-pain guideline recommendation for physicians on the web. Changes over-time at a global level were scrutinized at two time points 2011 for baseline and 2018 at first follow-up. Both anesthesiology and oncology societies were analyzed. RESULTS In 2011 we scrutinized 181,00 WebPages and 370 eligible societies were identified; 364 of these were eligible for analyses both in 2011 and 2018. The magnitude of cancer pain updated and evidence-based guideline recommendations on the web for health care providers was extremely low at global level and at any time point considered 1.1% (4/364) in 2011 and 4.7% (17/364) in 2018. Continental and intercontinental patterns, National's highest developmental index, oncology tradition and economic-geographic areas were not found to influence cancer pain web-guideline provision. In 2018, pain & supportive care societies provided the highest rate of updated evidence-based cancer-pain guidelines for clinicians. Only 3/25 medical oncology societies and 1/34 radiation oncology societies, provided own or e-link (to other societies') evidence-based guidelines in their websites. CONCLUSIONS Major medical oncology and radiation oncology societies - at global level - fail to produce updated cancer pain recommendations for their physicians, with most of these providing no or inconsistent or outdated guidelines.PURPOSE Surgical resection is the cornerstone of curative treatment for rectal adenocarcinomas. For extensive invasive tumors, preoperative radiotherapy and chemoradiotherapy have been utilized to promote tumor regression in an attempt to convert a planned abdominoperineal resection to a sphincter-sparing surgical procedure. In order to find out which of the currently radiation therapy treatment regimen used preoperatively for rectal cancer is the best we conducted a comprehensive literature search. METHODS We searched the Cochrane Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE database up to December 2018 for trials comparing the short and long term radiation therapy regimens for rectal carcinoma associated or not with chemotherapy. RESULTS The search of the literature identified 38 papers related to the subject. After analysis and evaluation, 11 eligible trials were included for review. The optimal fractionation and timing of surgery in relation to radiotherapy was still controversial. Randomized trials showed that if surgery is delayed after 5×5 Gy and consolidation chemotherapy is added between 5×5 Gy and surgery, such a combination results in better short term overall survival and lower acute toxicity. CONCLUSION Long-course radiotherapy with delay seems not to be different than short-course radiotherapy with delay, but prolongs substantially the treatment time.New non-invasive approaches have developed for diagnosis and treatment of malignant diseases. Cells shed from the primary tumor circulating in the bloodstream with metastasis potential are called Circulating Tumor Cells (CTCs). These cells are easily acquired from the peripheral blood of patients, while several enrichment and isolation methods are available nowadays with different benefits and positive detection rates. A brief characterization of three major categories of detection is described (nucleic acid-based, physical properties-based, antibody-based). In this review we concentrate on gynecological malignancies and how CTCs could be used in the diagnosis of cancer, treatment management and its effective prognosis and early recurrence detection. Presence of CTCs in endometrial cancer patients show worse overall survival, while gene analysis could identify patients in need of systemic therapy after surgical treatment to prevent metastasis and recurrence. Based on the influence of human papillomavirus (HPV) in the etiology of cervical cancer, viral oncogene transcripts could be used as an ideal marker for cervical cancer cells detection. In ovarian cancer, CTCs could help in the differentiation from benign adnexal masses and show a high independence from other biomarkers such as CA125 and HE4. While detection of CTC after complete cytoreductive surgery could indicate invisible lesions, combination of tumor associated genes rises the specificity of CTC detection.PURPOSE The purpose of this article was to review the current medical literature regarding deterioration of anorectal function in patients receiving neoadjuvant chemoradiotherapy before surgery for locally advanced rectal cancer. METHODS We reviewed the current literature including research studies, electronic database PUBMED-MEDLINE, published research results and metanalysis papers from high-volume institutes, collecting and comparing the different results. Pathophysiology as well as emerging solutions for treating anorectal sphincter dysfunction were researched in order to provide an insight of this complex issue. RESULTS All available data suggest that neoadjuvant radiation therapy impairs internal anal sphincter function mostly through nerve damaging mechanisms, as nerves are more susceptible to damage than muscular fibers. CONCLUSION Current radiotherapy recommendations are oriented in exclusion of anal canal from radiation field when oncologically safe or using new sphincter-sparing techniques for neoadjuvant radiotherapy aiming to improve the patient quality of life receiving radiation therapy prior to surgery.
My Website: https://www.selleckchem.com/products/triiodothyronine.html